Healthcare -
Drug Manufacturers - General - NYSE - US
$ 22.445
-0.452 %
$ 127 B
Market Cap
15.63
P/E
1. INTRINSIC VALUE
Balance Sheet
Pfizer Inc.
| Current Assets | 50.4 B |
| Cash & Short-Term Investments | 20.5 B |
| Receivables | 14.8 B |
| Other Current Assets | 15.1 B |
| Non-Current Assets | 163 B |
| Long-Term Investments | 2.23 B |
| PP&E | 18.4 B |
| Other Non-Current Assets | 142 B |
| Current Liabilities | 43 B |
| Accounts Payable | 5.63 B |
| Short-Term Debt | 6.95 B |
| Other Current Liabilities | 30.4 B |
| Non-Current Liabilities | 81.9 B |
| Long-Term Debt | 56.7 B |
| Other Non-Current Liabilities | 25.2 B |
EFFICIENCY
Earnings Waterfall
Pfizer Inc.
| Revenue | 63.6 B |
| Cost Of Revenue | 16.4 B |
| Gross Profit | 47.2 B |
| Operating Expenses | 25.6 B |
| Operating Income | 14.9 B |
| Other Expenses | 6.89 B |
| Net Income | 8.05 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pfizer Inc.
| Net Income | 8.05 B |
| Depreciation & Amortization | 7.01 B |
| Capital Expenditures | -2.91 B |
| Stock-Based Compensation | 877 M |
| Change in Working Capital | -3.07 B |
| Others | 891 M |
| Free Cash Flow | 9.84 B |
Wall Street Analysts Price Targets
Pfizer Inc.
Wall Street analysts predict an average 1-year price target for PFE of $32.9 , with forecasts ranging from
a
low of
$30 to a high of $36 .
PFE Lowest Price Target
Wall Street Target
30 USD
33.66%
PFE Average Price Target
Wall Street Target
32.9 USD
46.58%
PFE Highest Price Target
Wall Street Target
36 USD
60.39%
4. DIVIDEND
ANALYSIS
1.58%
DIVIDEND YIELD
0.43 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Pfizer Inc.
Sold
0-3 MONTHS
64.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
148 K USD 1
9-12 MONTHS
0 USD 0
Bought
499 K USD 1
0-3 MONTHS
28.2 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
barrons.com
- 1 week ago
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 week ago
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
- 1 week ago
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025)
Shares of Pfizer ( NYSE: PFE ) have been battered over the past month, falling by -16.44%, outpacing the market's loss of -9.44% over the same period.
247wallst.com
- 1 week ago
3 High Yielding Dividend Stocks Near 52-Week Lows
2025 hasn't been kind to investors amid rising concerns about a recession and tariffs.
247wallst.com
- 1 week ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
fxempire.com
- 1 week ago
Pfizer: Is The Dividend Yield Worth The Effort
Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic focus on R&D, cost-cutting, and new revenue streams from acquisitions aims to mitigate upcoming revenue losses and drive future growth. Despite current challenges, Pfizer's robust cash flow, cost-saving initiatives, and potential new blockbusters by 2030 present a speculative but promising investment opportunity.
seekingalpha.com
- 1 week ago
3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap
Every cloud has a silver lining. Sometimes, they have two.
fool.com
- 1 week ago
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration. At the time of writing, the S&P 500 index is down about 8% year to date.
fool.com
- 1 week ago
If You Like Schwab's SCHD, You Can't Miss These Stocks With Even Higher Yields
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors who want both quality and yield.
247wallst.com
- 2 weeks ago
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.
fool.com
- 2 weeks ago
3 Magnificent S&P 500 Dividend Stocks Down 11% to 63% to Buy and Hold Forever
The past few weeks have been tough for the market. Tariffs are obviously a direct threat to most companies' top and bottom lines, while the broad economic weakness they might cause is nearly impossible to predict.
fool.com
- 2 weeks ago
8. Profile
Summary
Pfizer Inc. PFE
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 127 B
Dividend Yield
1.58%
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact
235 East 42nd Street, New York, NY, 10017
https://www.pfizer.com
IPO
Date
June 1, 1972
Employees
81000
Officers
Dr. Michael S. Vincent M.D., Ph.D.
Senior Vice President and Chief Scientific Officer of Inflammation & Immunology
Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & Chief Executive Officer
Ms. Jennifer B. Damico
Senior Vice President, Controller & Principal Accounting Officer
Ms. Lidia L. Fonseca
Executive Vice President and Chief Digital & Technology Officer
Ms. Payal Sahni Becher
Chief People Experience Officer & Executive Vice President
Mr. Douglas M. Lankler
Executive Vice President & Chief Legal Officer
Ms. Sally M. Susman
Executive Vice President & Chief Corporate Affairs Officer
Ms. Francesca M. DeMartino
Chief Investor Relations Officer
Dr. Chris Boshoff FMedSci, M.D., Ph.D.
Chief Scientific Officer and President of Research & Development
Mr. David M. Denton
Chief Financial Officer & Executive Vice President